-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Migraine is a chronic, intermittent primary headache disorder characterized by moderate to severe pain and specific associated features, including nausea/vomiting, photophobia, and phonophobia
About one-third of migraine sufferers have aura symptoms, which are short-lived neurological symptoms (most commonly visual disturbances) that precede the onset of headaches caused by changes in brain activity
Vascular Hypertension As a result, many experts have included migraine in their CVD risk scores
JAMA
Participants in the study, adults aged 18 to 65 with episodic or chronic migraine headaches, were randomized to receive irectinib or a placebo
Of the 2682 patients randomly assigned in 4 trials, 1400 (52.
Overall, in patients with and without a history of aura, the erenazumab group had greater reductions in MMDs and AMSM days than the placebo group, and these reductions were maintained throughout the expansion phase
Differences in MMDs and AMSM days according to history of episodic migraine aura
In patients with a history of episodic migraine and aura, the change from baseline in MMDs was -1.
Among patients with chronic migraine with aura, the mean difference from placebo treatment was -2.
In migraine patients with and without aura, migraine frequency and AMSM days were reduced with irelumab treatment
references:
Ashina M, Goadsby PJ, Dodick DW, et al.
leave a message here
